Cantor Fitzgerald Comments on Elutia FY2026 Earnings

Elutia Inc. (NASDAQ:ELUT - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Elutia in a report released on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings of ($0.17) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $8.00 target price on the stock. The consensus estimate for Elutia's current full-year earnings is ($1.74) per share.

Separately, Lake Street Capital reduced their price target on shares of Elutia from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, May 9th.

Elutia Stock Performance

Elutia stock traded up $0.02 during trading on Tuesday, reaching $2.01. The company had a trading volume of 18,361 shares, compared to its average volume of 50,807. Elutia has a 12-month low of $1.61 and a 12-month high of $5.24. The stock's 50 day moving average price is $2.04 and its two-hundred day moving average price is $2.90. The firm has a market capitalization of $82.64 million, a price-to-earnings ratio of -0.77 and a beta of 0.86.

Elutia (NASDAQ:ELUT - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The company had revenue of $6.03 million for the quarter, compared to analysts' expectations of $6.65 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. OMERS ADMINISTRATION Corp acquired a new position in Elutia during the first quarter valued at approximately $28,000. Jane Street Group LLC acquired a new position in Elutia during the first quarter valued at approximately $48,000. Arcus Capital Partners LLC acquired a new position in Elutia during the first quarter valued at approximately $51,000. Northern Trust Corp lifted its position in Elutia by 30.0% during the fourth quarter. Northern Trust Corp now owns 17,957 shares of the company's stock valued at $67,000 after buying an additional 4,148 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of Elutia during the fourth quarter worth $84,000. 74.03% of the stock is owned by institutional investors and hedge funds.

About Elutia

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.